Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of Standard of Care Treatment Versus Mesenchymal Stromal Cell Therapy Together With Standard of Care for the Treatment of de Novo Acute Graft Versus Host Disease Following Allogeneic Bone Marrow Transplantation

NCT01589549 is registered in ClinicalTrials.gov with R.P.Herrmann as lead sponsor.

NCT NCT01589549
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01589549 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of Standard of Care Treatment Versus Mesenchymal Stromal Cell Therapy Together With Standard of Care for the Treatment of de Novo Acute Graft Versus Host Disease Following Allogeneic Bone Marrow Transplantation
Lead sponsor
R.P.Herrmann
Phase
Phase 2
Overall status
Unknown status
Start date
April 30, 2012
Completion date
December 31, 2016
Enrollment
66 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute gvh disease